Emphysema Treatment Market

Market Overview The global market for emphysema treatment is projected to expand significantly, increasing from USD 4.54 Billion in 2025 to USD 6.49 Billion by 2031, demonstrating a compound annual growth rate of 6.14%. This market addresses the management of alveolar destruction and aims to enhance respiratory function through various therapeutic approaches, which include pharmacological options like bronchodilators and corticosteroids, as well as lung volume reduction procedures. A major impetus for this growth stems from the rising worldwide incidence of tobacco smoking, ongoing exposure to environmental pollutants, and a growing elderly population that is particularly vulnerable to progressive respiratory decline. These elements collectively fuel a sustained need for effective treatment strategies, independent of advancements in drug delivery technology. Nevertheless, the market encounters substantial obstacles, primarily due to the elevated costs associated with advanced therapeutic options and strict regulatory demands that frequently postpone the market entry of new treatments. The COPD Foundation reported in 2025 that over 30 million individuals in the United States were estimated to be affected by chronic obstructive pulmonary disease, highlighting a considerable, though frequently undiagnosed, patient population in urgent need of readily available therapeutic interventions. Market Driver The market is being significantly transformed by the emergence of new biologics and triple-combination therapies, which target specific inflammatory pathways previously beyond the scope of conventional bronchodilator treatments. Recent regulatory approvals have paved the way for therapies that act on phosphodiesterase inhibitors and type 2 inflammation, providing substantial advantages for patients experiencing frequent exacerbations and presenting with moderate to severe conditions. This paradigm shift in treatment is underscored by swift market penetration, as exemplified by Verona Pharma's report in April 2025, which showed net product sales of $71.3 million for its recently introduced maintenance therapy, Ohtuvayre, in its First Quarter 2025 Financial Results. Such innovations are increasingly critical given that ongoing exposure to environmental pollutants continues to expand the population requiring advanced medical attention; the American Lung Association noted in 2025 that 156 million Americans resided in areas with substandard air quality, thus perpetuating the strong demand for effective respiratory interventions. Concurrently, the increasing embrace of minimally invasive lung volume reduction (LVR) procedures serves as another key market driver, particularly for cases of severe emphysema where pharmacological interventions alone are inadequate. Endobronchial valves are gaining preference over more intrusive surgical alternatives because they offer quicker recovery periods and effectively block diseased lung segments to enhance breathing mechanics. This sector is experiencing robust growth as healthcare systems worldwide adopt updated treatment protocols that advocate for these interventional tools. For example, Pulmonx Corporation reported global revenue of $21.5 million in its Third Quarter 2025 Financial Results in November 2025, which highlights the growing international use of its Zephyr Valve system for treating severe emphysema. Market Challenge A significant obstacle facing the Global Emphysema Treatment Market is the prohibitive cost of advanced therapies, coupled with stringent regulatory demands. These financial and procedural hurdles directly impede market expansion by limiting patient access to essential treatments and prolonging the market entry of new products. Both sophisticated pharmacotherapies and lung volume reduction procedures are often premium-priced, imposing considerable financial strain on healthcare systems and individuals without adequate insurance. This leads to reduced adoption rates in cost-sensitive regions, thereby restricting potential revenue growth for manufacturers. Moreover, rigorous regulatory environments demand substantial capital investment and extended clinical trial periods, escalating the financial risks for companies developing innovative therapeutics. The broader economic consequences of respiratory illnesses on productivity further illustrate this financial burden. A 2025 joint report from the World Health Organization and the European Respiratory Society indicated that the regional productivity loss due to chronic respiratory diseases was approximately US$20.7 billion. This statistic underscores the profound economic repercussions stemming from restricted access to treatment. The persistence of high costs and regulatory setbacks forms a bottleneck, hindering the market's ability to fully leverage increasing demand and effectively stifling growth, even amidst the rising prevalence of emphysema. Market Trends Robotic-assisted interventional bronchoscopy systems are profoundly transforming the treatment approaches for emphysema by offering precise entry into peripheral lung areas that were previously inaccessible through traditional techniques. These advanced robotic systems incorporate shape-sensing technology and extremely thin catheters, providing enhanced stability and the ability to reach deep into distal airways. This enables pulmonologists to conduct biopsies or administer treatments with significantly improved accuracy and safety. This capability is especially crucial for individuals with emphysema who have compromised lung structures, as it substantially reduces the risk of pneumothorax often linked with percutaneous needle procedures and allows for earlier intervention in challenging cases. The market's strong inclination towards these automated guidance tools is demonstrated by their swift integration into clinical practice, with Intuitive Surgical reporting a 58% increase in Ion procedures in April 2025 compared to the prior year's first quarter, signaling a substantial growth in the use of robotic respiratory interventions. Concurrently, the deployment of remote digital respiratory monitoring solutions is revolutionizing the long-term management of emphysema, transitioning care from a reactive acute model to one of continuous, data-informed support within the home environment. These digital platforms incorporate cloud-connected therapeutic devices that diligently monitor vital parameters like airflow, treatment adherence, and leak rates, relaying real-time data to healthcare professionals to proactively prevent exacerbations. This interconnected approach not only decreases hospital readmission rates but also enhances resource efficiency by enabling clinicians to modify treatment regimens remotely, eliminating the need for in-person office visits. The commercial success of this digital health paradigm is confirmed by the increasing revenues of prominent medical device companies; ResMed Inc.'s Residential Care Software segment, for instance, reported revenue of $641.4 million in August 2025, a 10% rise from the previous fiscal year, underscoring the growing dependence on integrated software solutions for managing respiratory health. Key Market Players * Icure Pharmaceuticals Inc. * AstraZeneca Plc. * Teva Pharmaceuticals Industries Ltd. * Novartis AG * GlaxoSmithKline Plc. * Hikma Pharmaceuticals Plc * Boehringer Ingelheim International GmbH * Mylan N.V. * Pfizer Inc. * Orion Corporation Report Scope In this report, the Global Emphysema Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Emphysema Treatment Market, By Treatment * Smoking Cessation * Bronchodilators * Steroids * Leukotriene Modifiers * Supplemental Oxygen * Antibiotics * Gene Therapy * Surgery Transplant * Other Treatments # Emphysema Treatment Market, By Distribution Channel * Hospital Pharmacy * Retail Pharmacy * Other Distribution Channels # Emphysema Treatment Market, By End-User * Hospitals & Clinics * Ambulatory Surgical Centers * Others # Emphysema Treatment Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Emphysema Treatment Market. Available Customizations: Global Emphysema Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).